Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A Phase II, Open-Label, Multicohort, Multicenter Study in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh B Cirrhosis

    Cancer Categories
    • Gastrointestinal (GI)
    Karmanos Trial ID
    • 2023-105
    NCT ID
    • NCT06096779
    Age Group
    • Adult
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase II
    Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
    • Phase II
    Principal Investigator
    • Mohammed Najeeb
      Al Hallak, M.D., MS

      Oncology - Medical View Profile


    Primary Objective:

    • To evaluate the safety of the study treatments in Cohorts A and B

    Secondary Objectives:

    • To evaluate the efficacy of the study treatments in Cohorts A and B
    • To evaluate patient-reported tolerability of the study treatments in Cohorts A and B from the participant’s perspective
  • Locations


    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266